Krabeva 400 mg Injection
  1. Home
  2. Pharma Products
  3. Biocon
  4. Krabeva 400 mg Injection

Krabeva 400 mg Injection

Krabeva 400 mg Injection contains bevacizumab, a targeted monoclonal antibody used in the treatment of several cancers. It is supplied as a 400 mg/16 mL concentrate for intravenous infusion. Bevacizumab works by blocking VEGF and reducing the blood supply that tumors need for growth.

BUY NOW

Category

Krabeva 400 mg Injection is used in combination with appropriate anticancer treatment for conditions such as metastatic colorectal cancer, certain breast cancers, nonsquamous non-small cell lung cancer, and renal cell cancer. Bevacizumab binds to vascular endothelial growth factor and inhibits the formation of new blood vessels that support tumor growth. The medicine is administered by intravenous infusion by a qualified healthcare professional and should not be self-administered. Patients require medical monitoring for infusion reactions, blood pressure changes, bleeding, and other treatment-related effects.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 400 mg
Concentration 25 mg/mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Pack Size 1 Vial, 16 mL

Product Also Known As

Krabeva 400 mg Injection, Bevacizumab 400 mg Injection, Krabeva Bevacizumab Injection, Bevacizumab Cancer Injection, Anti-VEGF Injection, Targeted Cancer Therapy Injection